Catalog No.
RHP01301
Species reactivity
Human
Host species
Mouse
Isotype
IgG1
Clonality
Monoclonal
Tested applications
IHC: 1:100-1:200
Target
Spindle apparatus coiled-coil domain-containing protein 1, Coiled-coil domain-containing protein 99, Protein Spindly, Arsenite-related gene 1 protein, SPDL1, Rhabdomyosarcoma antigen MU-RMS-40.4A, CCDC99, hSpindly
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q96EA4
Applications
IHC
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.05% Sodium Azide.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
R4C36
N-glycosylation of PD-L1 modulates the efficacy of immune checkpoint blockades targeting PD-L1 and PD-1., PMID:40346531
Macrophage-Tased Dual-Phase T Cell Immunomodulation to Combat Transplant Rejection., PMID:40264278
Secreted PD-L1 alleviates inflammatory arthritis in mice through local and systemic AAV gene therapy., PMID:39963137
Immune checkpoint molecules performance in ANCA vasculitis., PMID:39537557
Soluble Immune Checkpoints Associated With Disease Activity and Treatment Response in GD and TED., PMID:39475457
Efficacy of durvalumab plus chemotherapy in advanced biliary duct cancer and biomarkers exploration., PMID:39235609
Effect of Follicular T Helper and T Helper 17 Cells-Related Molecules on Disease Severity in Patients with Myasthenia Gravis., PMID:39168115
An observational study investigating soluble immune checkpoints as indicators of severe COVID-19., PMID:38809008
Lysosomal degradation of PD-L1 is associated with immune-related adverse events during anti-PD-L1 immunotherapy in NSCLC patients., PMID:38799168
Soluble programmed death ligand 1 as prognostic biomarker in non-small cell lung cancer patients receiving nivolumab, pembrolizumab or atezolizumab therapy., PMID:38637655
Soluble PD-L1 predicts tumor response and immune-related adverse events in patients with advanced melanoma treated with anti-PD-1 antibodies., PMID:38433350
Plasma sPD-L1 and VEGF levels are associated with the prognosis of NSCLC patients treated with combination immunotherapy., PMID:38386011
Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma., PMID:38228729
The combination of soluble forms of PD-1 and PD-L1 as a predictive marker of PD-1 blockade in patients with advanced cancers: a multicenter retrospective study., PMID:38149256
Soluble PD-L1 changes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors: an individual patient data meta-analysis., PMID:38115995
Association of plasma sPD-1 and sPD-L1 with disease status and future relapse in AQP4-IgG (+) NMOSD., PMID:38069466
Enzyme-catalyzed electrochemical aptasensor for ultrasensitive detection of soluble PD-L1 in breast cancer based on decorated covalent organic frameworks and carbon nanotubes., PMID:37923412
Timing of anti-PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma., PMID:37903325
The influence of plasma sPD-L1 concentration on the effectiveness of immunotherapy in advanced NSCLC patients., PMID:37816808
Dynamics of Soluble Forms of the Immune Checkpoint Components PD-1/PD-L1/B7-H3, CD314/ULBP1, and HLA-G in Peripheral Blood of Melanoma Patients Receiving Blockers of Programmed Cell Death Protein PD-1., PMID:37773572
Serum immune mediators as novel predictors of response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients with high tissue-PD-L1 expression., PMID:37256148
Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors., PMID:37188764
Immune Checkpoint Profiling in Humanized Breast Cancer Mice Revealed Cell-Specific LAG-3/PD-1/TIM-3 Co-Expression and Elevated PD-1/TIM-3 Secretion., PMID:37174080
Association between response to anti-PD-1 treatment and blood soluble PD-L1 and IL-8 changes in patients with NSCLC., PMID:36991160
Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab: Blood-based biomarker analysis for the DELIVER trial., PMID:36889037
Blocking of programmed cell death-ligand 1 (PD-L1) expressed on endothelial cells promoted the recruitment of CD8+IFN-γ+ T cells in atherosclerosis., PMID:36867228
Soluble TIM-3 as a biomarker of progression and therapeutic response in cancers and other of human diseases., PMID:36739094
Prognostic Value of Serum Soluble PD-L1 in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab., PMID:36697079
Soluble programmed death ligand-1-induced immunosuppressive effects on chimeric antigen receptor-natural killer cells targeting Glypican-3 in hepatocellular carcinoma., PMID:36640111
Role of soluble forms of follicular helper T-cell membrane molecules in the pathogenesis of myasthenia gravis., PMID:36621075
Soluble immune checkpoint molecules in patients with antineutrophil cytoplasmic antibody-associated vasculitis., PMID:36494415
Differential expression of circulating miRNAs after alemtuzumab induction therapy in lung transplantation., PMID:35490174
Role of Soluble T-Cell Immunoglobulin Mucin Domain-3 in Differentiating Nontuberculous Mycobacterial Lung Disease from Pulmonary Colonization., PMID:35312611
Cellular and soluble immune checkpoint signaling forms PD-L1 and PD-1 in renal tumor tissue and in blood., PMID:35184226
Soluble PD-L1 as an early marker of progressive disease on nivolumab., PMID:35131863
The expression and function of programmed death-ligand 1 and related cytokines in neutrophilic asthma., PMID:35071421
A Dual-Channel Intelligent Point-of-Care Testing System for Soluble Programmed Death-1 and Programmed Death-Ligand 1 Detection Based on Folding Paper-Based Immunosensors., PMID:35060694
Circular RNA hsa_circ_0000190 Facilitates the Tumorigenesis and Immune Evasion by Upregulating the Expression of Soluble PD-L1 in Non-Small-Cell Lung Cancer., PMID:35008490
In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-l/PD-L1 interaction., PMID:34996924
Neutrophil Extracellular Traps Promote T Cell Exhaustion in the Tumor Microenvironment., PMID:34899751
Soluble PD-L1 as a predictive biomarker in lung cancer: a systematic review and meta-analysis., PMID:34874185
Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases., PMID:34204509
Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma., PMID:33956203
Specific intracellular binding peptide as sPD-L1 antibody mimic: Robust binding capacity and intracellular region specific modulation upon applied to sensing research., PMID:33930752
Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: A phase-2 nonrandomized clinical trial., PMID:33636027
Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy., PMID:33329567
Immune checkpoint expression on peripheral cytotoxic lymphocytes in cervical cancer patients: moving beyond the PD-1/PD-L1 axis., PMID:33306195
HGF-Induced PD-L1 Expression in Head and Neck Cancer: Preclinical and Clinical Findings., PMID:33233528
The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes., PMID:33224142
Soluble programmed death-1 (sPD-1) as predictor of early surgical outcomes of paediatric cystic echinococcosis., PMID:33207012
For research use only. Not for human or drug use.
